BRPI0916021B8 - grânulo de ácido gama-hidroxibutírico, composição farmacêutica e processo de preparação de um grânulo - Google Patents

grânulo de ácido gama-hidroxibutírico, composição farmacêutica e processo de preparação de um grânulo

Info

Publication number
BRPI0916021B8
BRPI0916021B8 BRPI0916021A BRPI0916021A BRPI0916021B8 BR PI0916021 B8 BRPI0916021 B8 BR PI0916021B8 BR PI0916021 A BRPI0916021 A BR PI0916021A BR PI0916021 A BRPI0916021 A BR PI0916021A BR PI0916021 B8 BRPI0916021 B8 BR PI0916021B8
Authority
BR
Brazil
Prior art keywords
granule
gamma
hydroxybutyric acid
preparing
pharmaceutical composition
Prior art date
Application number
BRPI0916021A
Other languages
English (en)
Portuguese (pt)
Inventor
Lebon Christophe
Suplie Pascal
Original Assignee
Debregeas Et Associes Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40674006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0916021(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Debregeas Et Associes Pharma filed Critical Debregeas Et Associes Pharma
Publication of BRPI0916021A2 publication Critical patent/BRPI0916021A2/pt
Publication of BRPI0916021B1 publication Critical patent/BRPI0916021B1/pt
Publication of BRPI0916021B8 publication Critical patent/BRPI0916021B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0916021A 2008-11-14 2009-11-10 grânulo de ácido gama-hidroxibutírico, composição farmacêutica e processo de preparação de um grânulo BRPI0916021B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0857763A FR2938431B1 (fr) 2008-11-14 2008-11-14 Nouvelle composition a base d'acide gamma-hydroxybutyrique
PCT/FR2009/052169 WO2010055260A1 (fr) 2008-11-14 2009-11-10 Nouvelle composition à base d'acide gamma-hydroxybutyrique

Publications (3)

Publication Number Publication Date
BRPI0916021A2 BRPI0916021A2 (pt) 2015-11-10
BRPI0916021B1 BRPI0916021B1 (pt) 2020-01-14
BRPI0916021B8 true BRPI0916021B8 (pt) 2021-05-25

Family

ID=40674006

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0916021A BRPI0916021B8 (pt) 2008-11-14 2009-11-10 grânulo de ácido gama-hidroxibutírico, composição farmacêutica e processo de preparação de um grânulo

Country Status (34)

Country Link
US (1) US8529954B2 (cg-RX-API-DMAC7.html)
EP (1) EP2349217B1 (cg-RX-API-DMAC7.html)
JP (1) JP2012508784A (cg-RX-API-DMAC7.html)
KR (1) KR101563390B1 (cg-RX-API-DMAC7.html)
CN (2) CN104688691A (cg-RX-API-DMAC7.html)
AR (1) AR074351A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009315441B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0916021B8 (cg-RX-API-DMAC7.html)
CA (1) CA2743767C (cg-RX-API-DMAC7.html)
CL (1) CL2011001114A1 (cg-RX-API-DMAC7.html)
CO (1) CO6382106A2 (cg-RX-API-DMAC7.html)
CU (1) CU20110109A7 (cg-RX-API-DMAC7.html)
CY (1) CY1122209T1 (cg-RX-API-DMAC7.html)
DK (1) DK2349217T3 (cg-RX-API-DMAC7.html)
EA (1) EA023305B1 (cg-RX-API-DMAC7.html)
ES (1) ES2749803T3 (cg-RX-API-DMAC7.html)
FR (1) FR2938431B1 (cg-RX-API-DMAC7.html)
HR (1) HRP20191911T1 (cg-RX-API-DMAC7.html)
HU (1) HUE046321T2 (cg-RX-API-DMAC7.html)
IL (1) IL212847A (cg-RX-API-DMAC7.html)
LT (1) LT2349217T (cg-RX-API-DMAC7.html)
MA (1) MA32790B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011005073A (cg-RX-API-DMAC7.html)
NZ (1) NZ592850A (cg-RX-API-DMAC7.html)
PE (1) PE20120028A1 (cg-RX-API-DMAC7.html)
PL (1) PL2349217T3 (cg-RX-API-DMAC7.html)
PT (1) PT2349217T (cg-RX-API-DMAC7.html)
SI (1) SI2349217T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900721T1 (cg-RX-API-DMAC7.html)
TN (1) TN2011000231A1 (cg-RX-API-DMAC7.html)
TW (1) TWI446906B (cg-RX-API-DMAC7.html)
UA (1) UA103057C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010055260A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201103542B (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2949062B1 (fr) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
FR2949061B1 (fr) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
BR112012024019B1 (pt) 2010-03-24 2021-10-19 Jazz Phamaceuticals, Inc Forma de dosagem de liberação controlada para administração oral
FR2971422B1 (fr) * 2011-02-11 2016-05-20 Debregeas Et Associes Pharma Granules d'acide gamma-hydroxybutyrique
US9050302B2 (en) * 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
CA3200357A1 (en) * 2017-12-20 2019-06-27 Flamel Ireland Limited Packaged modified release gamma-hydroxybutyrate formulations having improved stability
US11400052B2 (en) 2018-11-19 2022-08-02 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
AU2020231916B2 (en) 2019-03-01 2025-08-28 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
WO2021127461A1 (en) 2019-12-20 2021-06-24 Xw Laboratories Limited Methods of synthesizing 4-valyloxybutyric acid
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
AU2021292406B2 (en) 2020-06-18 2024-03-14 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
KR20230008190A (ko) * 2020-06-18 2023-01-13 엑스더블유파마 리미티드 수용성 원료의약품의 약학적 과립화제
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
AU2021357705B2 (en) 2020-10-05 2024-09-26 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
CN112868909A (zh) * 2021-01-22 2021-06-01 湖北神舟化工有限公司 一种无臭型丁酸钠及其生产方法
EP4308086B1 (en) 2021-03-19 2025-10-15 XWPharma Ltd. Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative
CN117157060A (zh) * 2021-04-16 2023-12-01 南京纽邦生物科技有限公司 包衣β-羟基丁酸晶体及其制备方法
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
CN117413958A (zh) * 2023-12-04 2024-01-19 湖北中烟工业有限责任公司 一种加热不燃烧烟草制品发烟段物料及其制作工艺和加热不燃烧烟草制品

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4101650A (en) 1977-04-06 1978-07-18 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Pepstatin floating minicapsules
US4424235A (en) 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
IT1217783B (it) * 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative
IT1248588B (it) * 1991-06-28 1995-01-19 Gaetano Crepaldi Composizioni farmaceutiche per la terapia dell'astinenza, del " craving", della dipendenza da sostanze stupefacenti, da sostanze psicoattive, da nicotina e dei disturbi alimentari.
IT1266565B1 (it) * 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US6214386B1 (en) 1995-11-22 2001-04-10 Recordati, S.A. Prompt-release oral pharmaceutical compositions for extemporaneous suspensions
US5846971A (en) 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
US6649186B1 (en) 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
JP3447042B2 (ja) * 1997-07-23 2003-09-16 フロイント産業株式会社 単一物質球形粒の製造方法
GB9725219D0 (en) 1997-11-29 1998-01-28 Cleansharp Ltd Tablets
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
ATE238783T1 (de) * 1998-12-23 2003-05-15 Orphan Medical Inc Mikrobenbeständige und stabilisierte lösungen, die gamma-hydroxybuttersäuresalze zur behandlung von narkolepsie enthalten
FR2790668B1 (fr) * 1999-03-12 2002-07-26 D B F Granules contenant une substance vegetale et leur procede de preparation
ATE318585T1 (de) * 1999-05-17 2006-03-15 D B F Pflanzenmaterial enthaltendes granulat und verfahren zur herstellung
FR2797185B1 (fr) 1999-08-06 2001-10-26 Galenix Dev Composition pharmaceutique flottante comprenant une phase active et une phase non active
FR2823668B1 (fr) 2001-04-20 2004-02-27 Ethypharm Lab Prod Ethiques Comprimes effervescents orodispersibles
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
EP1414418A1 (en) 2001-08-06 2004-05-06 Euro-Celtique S.A. Compositions and methods to prevent abuse of opioids
US20030059397A1 (en) 2001-09-17 2003-03-27 Lyn Hughes Dosage forms
FR2829933B3 (fr) 2001-09-21 2004-03-12 Ellipse Pharmaceuticals Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs notamment de gout et produit obtenu
FR2829932B1 (fr) 2001-09-21 2006-11-24 Ellipse Pharmaceuticals Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs et produit obtenu
EP2422772A3 (en) * 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
MXPA06009991A (es) 2004-03-03 2007-04-10 Teva Pharma Una composicion farmaceutica estable que comprende un farmaco labil acido.
TW200533391A (en) 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
US8193211B2 (en) * 2004-09-30 2012-06-05 Supernus Pharmaceuticals, Inc. Controlled release compositions of gamma-hydroxybutyrate
ZA200711123B (en) 2005-06-27 2009-08-26 Biovail Lab Int Srl Modified-release formulations of a bupropion salt
US20070092565A1 (en) 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
EP2223702B1 (en) * 2007-12-03 2019-05-08 Tomita Pharmaceutical Co., Ltd. Core particle for pharmaceutical preparation
FR2949062B1 (fr) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
FR2949061B1 (fr) 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants

Also Published As

Publication number Publication date
EP2349217A1 (fr) 2011-08-03
IL212847A (en) 2015-02-26
PT2349217T (pt) 2019-11-04
KR20110099011A (ko) 2011-09-05
TW201031401A (en) 2010-09-01
KR101563390B1 (ko) 2015-11-06
EP2349217B1 (fr) 2019-07-31
US8529954B2 (en) 2013-09-10
AR074351A1 (es) 2011-01-12
TWI446906B (zh) 2014-08-01
ES2749803T3 (es) 2020-03-23
CN102215822A (zh) 2011-10-12
ZA201103542B (en) 2012-01-25
TN2011000231A1 (fr) 2012-12-17
IL212847A0 (en) 2011-07-31
MX2011005073A (es) 2011-10-12
CA2743767C (fr) 2019-06-25
JP2012508784A (ja) 2012-04-12
PL2349217T3 (pl) 2020-03-31
FR2938431B1 (fr) 2013-12-20
CL2011001114A1 (es) 2011-09-02
CN104688691A (zh) 2015-06-10
US20110293729A1 (en) 2011-12-01
WO2010055260A1 (fr) 2010-05-20
MA32790B1 (fr) 2011-11-01
PE20120028A1 (es) 2012-02-25
UA103057C2 (ru) 2013-09-10
CA2743767A1 (fr) 2010-05-20
FR2938431A1 (fr) 2010-05-21
BRPI0916021A2 (pt) 2015-11-10
EA201100758A1 (ru) 2011-12-30
HRP20191911T1 (hr) 2020-01-10
LT2349217T (lt) 2019-11-11
EA023305B1 (ru) 2016-05-31
CY1122209T1 (el) 2020-11-25
BRPI0916021B1 (pt) 2020-01-14
AU2009315441A1 (en) 2010-05-20
CU20110109A7 (es) 2012-01-31
DK2349217T3 (da) 2019-11-04
NZ592850A (en) 2012-11-30
HUE046321T2 (hu) 2020-02-28
SI2349217T1 (sl) 2020-01-31
CO6382106A2 (es) 2012-02-15
AU2009315441B2 (en) 2015-02-26
SMT201900721T1 (it) 2020-01-14

Similar Documents

Publication Publication Date Title
BRPI0916021B8 (pt) grânulo de ácido gama-hidroxibutírico, composição farmacêutica e processo de preparação de um grânulo
BRPI0908421C1 (pt) solução estável de um composto farmacêutico
BRPI0924136B8 (pt) composição farmacêutica sólida compreendendo amlodipina e losartan e método para a preparação da mesma
BRPI0910734A2 (pt) composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo.
BR112014009146A8 (pt) formulações de etanercepte estabilizadas com aminoácidos
UY32008A (es) Composición farmacéutica
BR112014017882A2 (pt) formulações estabilizadas contendo anticorpos anti-ang-2
BRPI0818533A2 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto
BR112013018635A2 (pt) carretel para o recebimento de material de enrolamento e sistema parcial de carretel
BRPI0915383A2 (pt) composto, métodos para tratar um indíviduo que sofre de um distúrbio neurodegenerativo ou psiquiátrico e para tratar um indivíduo que sofre de um vício em droga, e, composição farmacêutica.
BRPI0806957A2 (pt) Processo para produzir um ácido polilático, ácido polilático, e, artigo moldado.
BRPI0905147A8 (pt) processo para síntese de ivabradina e seus sais de adição com um ácido farmaceuticamente aceitável
EP2251011A4 (en) SOLID PREPARATION FOR ORAL ADMINISTRATION
BRPI0916936A2 (pt) composições faramacêuticas e métodos para produzir baixas concentrações de impureza da mesmas.
BR112015001414A2 (pt) composição antideriva
BR112013024424A2 (pt) recipiente, dispositivo de fixação, sistema de fixação e aplicador de injeção
BR112012026724A2 (pt) combinação de fármcos com pró-fármacos ligados à proteína
UY30191A1 (es) Procedimiento para evitar las precipitaciones de fluoroquinolonas en sus disoluciones por medio de compuestos de amonio cuaternario y medicamentos conteniéndolos
BRPI1014691A2 (pt) Composto, e, processo para a preparação de um composto.
BR112015024938A2 (pt) formulação, uso de formulações, e, processo para preparação de formulações
CL2007003593A1 (es) Composicion farmaceutica que comprende fluoresceina pura; procedimiento de preparacion de la fluoresceina.
CO6920289A2 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib.
BRPI0818885A2 (pt) Frasco, notadamente para máscara, comportando uma etiqueta com propriedades barreira e processo de fabricação.
BR112015011515A2 (pt) Composições farmacêuticas de inibidores de cetp
BR112015026631A2 (pt) compostos ou sais farmaceuticamente aceitáveis dos mesmos e respectivos usos, composição farmacêutica e método para prevenir ou tratar diabetes melito em mamífero

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/01/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/11/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.